FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns the treatment of leukemia. For this, an effective amount of 3-[(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330) or a pharmaceutically acceptable salt or solvate is introduced as monotherapy or in combination with other anti-leukemia compounds.
EFFECT: effective treatment of acute lymphoblastic leukemia in its various forms by means of the selective inhibitor of the Ref-1 redox function of the leukemia cells is provided.
3 cl, 9 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARING THE COMPOUNDS AND THEIR USE AS ATR KINASE INHIBITORS | 2019 |
|
RU2806857C2 |
| AGONISTS OF PROTEIN TYROSINE PHOSPHATASE-1 CONTAINING HOMOLOGY-2 SRC DOMAIN, AND METHODS OF TREATING USING SAID AGONISTS | 2012 |
|
RU2584986C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| VET PROTEIN DECOMPOSERS | 2017 |
|
RU2752677C2 |
| PHARMACEUTICAL COMPOSITIONS, COMPOUNDS, METHODS OF SYNTHESIS OF COMPOUNDS | 1995 |
|
RU2168995C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| COMBINATIONS OF DUAL MODULATORS IRS/STAT3 AND ANTIBODIES TO PD-1/PD-L1 FOR CANCER TREATMENT | 2017 |
|
RU2796275C2 |
| NEW SALICYLIC ACID DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALT, COMPOSITIONS AND METHOD FOR APPLICATION | 2013 |
|
RU2641903C2 |
| COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD DRUG FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | 2018 |
|
RU2792057C2 |
| BENZIMIDAZOLES USED AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2415853C2 |
